NEBCIN Drug Patent Profile
✉ Email this page to a colleague
When do Nebcin patents expire, and when can generic versions of Nebcin launch?
Nebcin is a drug marketed by Lilly and is included in four NDAs.
The generic ingredient in NEBCIN is tobramycin sulfate. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nebcin
A generic version of NEBCIN was approved as tobramycin sulfate by HIKMA on April 26th, 1991.
Summary for NEBCIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 78 |
Clinical Trials: | 1 |
Patent Applications: | 4,223 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NEBCIN at DailyMed |
Recent Clinical Trials for NEBCIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University Hospital, Lille | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for NEBCIN
US Patents and Regulatory Information for NEBCIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | NEBCIN | tobramycin sulfate | INJECTABLE;INJECTION | 050519-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lilly | NEBCIN | tobramycin sulfate | INJECTABLE;INJECTION | 050477-005 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lilly | NEBCIN | tobramycin sulfate | INJECTABLE;INJECTION | 062008-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |